Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Am J Hosp Palliat Care ; 34(1): 92-99, 2017 Feb.
Article in English | MEDLINE | ID: mdl-26443717

ABSTRACT

It has been reported that pain relief for patients with cancer is suboptimal in Japan. This has been mainly attributed to inadequate dissemination of the World Health Organization (WHO) guidelines for cancer pain management. To better understand this problem, we reviewed how 6 hospital palliative care teams (HPCTs) used the WHO guidelines for unrelieved pain in a 1-year audit that included 534 patients. The HPCT interventions were classified according to the contents of the WHO guidelines. In our study, HPCT interventions involved opioid prescriptions in >80% of referred patients, and "For the Individual" and "Attention to Detail" were the 2 most important principles. Our study indicates which parts of the WHO guidelines should be most heavily emphasized, when disseminating them in Japan.


Subject(s)
Cancer Pain/therapy , Guideline Adherence/statistics & numerical data , Pain Management/standards , Palliative Care/methods , Cancer Pain/prevention & control , Female , Humans , Japan , Male , Middle Aged , Pain Management/methods , Palliative Care/standards , Palliative Care/statistics & numerical data , Patient Care Team , Retrospective Studies , World Health Organization
2.
Cancer Epidemiol ; 39(6): 838-41, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26651443

ABSTRACT

OBJECTIVE: Dependent children under the age of 18 are particularly vulnerable to the stress of parental death from cancer or of having a parent diagnosed and treated for the disease. More and more Japanese couples are postponing parenthood, which increases their chances of developing cancer while they still have a dependent child. However, the problem has not received enough attention from healthcare professionals and policy-makers because the extent and breadth of the problem has never been examined in the Japanese population. Therefore, we aimed to estimate the nationwide incidence of cancer patients who have children under the age of 18 years, as well as the incidence of children who have a parent diagnosed with cancer in Japan. STUDY DESIGN: We calculated the proportion of patients who have children stratified by age, gender and cancer type using electronic medical records of cancer patients (20-59 years old) admitted to the National Cancer Center Hospital (NCCH) for the first time between January 2009 and December 2013. We projected these estimates onto the Japanese population using 2010 population-based cancer registry data, and repeated the projection using 2011 hospital-based cancer registry data so that estimates of patients receiving care at Designated Cancer Care (DCC) hospitals could be obtained. RESULTS: We found that an estimated 56,143 cancer patients who have 87,017 dependent children are diagnosed with cancer every year in Japan. The proportion of children in Japan who had a parent newly diagnosed with cancer in 2010 was approximately 0.38%. We estimated that in 2011 there were on average about 82 cancer patients with minor children and 128 minor children who have at least one parent diagnosed with cancer in every DCC hospital in Japan. CONCLUSION: Parental cancer is common. We have identified that many adults diagnosed with cancer have the double burden of coping with the diagnosis and treatment as well as supporting their children through this experience. Additional data on socioeconomic characteristics and needs assessment of these patients are required to understand how best to help children and families cope with cancer.


Subject(s)
Child of Impaired Parents/psychology , Child of Impaired Parents/statistics & numerical data , Neoplasms/epidemiology , Neoplasms/psychology , Parents , Adolescent , Adult , Child , Child, Preschool , Female , Humans , Incidence , Infant , Japan , Male , Middle Aged , Parents/psychology
3.
J Pain Symptom Manage ; 43(6): 1001-12, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22651946

ABSTRACT

CONTEXT: Although an evidence-based clinical guideline for parenteral hydration therapy was established in Japan, the efficacy of the guideline has not been assessed. OBJECTIVES: Our purpose was to explore the effect of parenteral hydration therapy based on this clinical guideline on quality of life (QoL), discomfort, symptoms, and fluid retention signs in patients with advanced cancer. METHODS: This multicenter, prospective, observational study included 161 patients with advanced abdominal cancer who received guideline-based hydration therapy. We evaluated the longitudinal changes of the global QoL (Item 30 of European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire-C30); the Discomfort Scale; the intensity of seven physical symptoms; and the severity of fluid retention signs. We also evaluated patient satisfaction and the feeling of benefit from hydration one week after the study commenced, and bronchial secretions, hyperactive delirium, communication capacity, and agitation 48 hours before a patient's death. RESULTS: The global QoL, the Discomfort Scale, and the intensities of all physical symptoms, except for vomiting and drowsiness, were stable throughout the study period. More than 80% of patients maintained all fluid retention signs. Patient global satisfaction was 76.4 (0-100) and feeling of benefit was 5.43 (range 0-7). CONCLUSION: Guideline-based parenteral hydration therapy contributed to maintaining global QoL and provided satisfaction and a feeling of benefit without increasing discomfort and worsening symptoms and fluid retention signs in patients with advanced cancer.


Subject(s)
Fluid Therapy , Neoplasms/mortality , Neoplasms/nursing , Parenteral Nutrition , Quality of Life , Terminal Care/statistics & numerical data , Aged , Comorbidity , Female , Fluid Therapy/mortality , Fluid Therapy/standards , Humans , Japan , Male , Pain/mortality , Pain/prevention & control , Parenteral Nutrition/mortality , Parenteral Nutrition/standards , Patient Satisfaction/statistics & numerical data , Practice Guidelines as Topic , Prevalence , Risk Factors , Stress, Psychological/epidemiology , Stress, Psychological/prevention & control , Survival Analysis , Survival Rate , Terminal Care/standards , Treatment Outcome
4.
Am J Hosp Palliat Care ; 26(2): 112-8, 2009.
Article in English | MEDLINE | ID: mdl-19114602

ABSTRACT

PURPOSE: Baclofen is a g-aminobutyric acid receptor agonist commonly used for managing many types of neuropathic pain. The effect of baclofen on cancer pain has not previously been studied. This retrospective study evaluated the efficacy of baclofen in patients with cancer pain. METHODS: We reviewed the medical records of all patients given baclofen orally as an analgesic for cancer at 5 institutions. RESULT: Twenty-five patients received 10 to 40 mg of baclofen for cancer pain relief. Twenty patients have undergone neuropathic pain such as paroxysmal or lancing, sharp, or like an electric shock. Baclofen was effective in 21 of 25 patients and significantly reduced Numeric Rating Scale (pain score, 0-10; P < .0001). Nine patients reported mild adverse events: none of these 9 patients had to discontinue baclofen due to adverse events. CONCLUSION: Our findings suggest that baclofen may be a useful adjuvant analgesic in the treatment of cancer pain.


Subject(s)
Analgesics/therapeutic use , Baclofen/therapeutic use , Pain, Intractable/drug therapy , Chemotherapy, Adjuvant/methods , Dose-Response Relationship, Drug , Female , Humans , Male , Neoplasms/complications , Pain Measurement/methods , Pain, Intractable/etiology , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...